Pharmacokinetics of oral mycophenolate mofetil in combination with CsA in dogs after nonmyeloablative allogeneic hematopoietic stem cell transplantation

Bone Marrow Transplantation

Volumn 41, Issue 7, 2008, Pages 667-674

  Lange, S ^a   Mueller, S C ^a   Altmann, S ^a   Dahlhaus, M ^a   Drewelow, B ^a   Freund, M ^a   Junghanss, C ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; LEUKOCYTE ANTIGEN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; GRAFT REJECTION; GRAFT VERSUS HOST REACTION; NONHUMAN; PRIORITY JOURNAL; WHOLE BODY RADIATION;

ANIMALS; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GRAFT REJECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE AGENTS; MYCOPHENOLIC ACID;

EID: 42149182357     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705958     Document Type: Article

References (32)

1. Sollinger HW, Belzer FO, Deierhoi MH, Diethelm AG, Gonwa TA, Kauffman RS et al. S-61443 (mycophenolate mofetil). A multicenter study for refractory kidney transplant rejection. Ann Surg 1992; 216: 513-518.
2. Ensley RD, Bristow MR, Olsen SL, Taylor DO, Hammond EH, O'Connell JB et al. The use of mycophenolate mofetil (RS-61443) in human heart transplant recipients. Transplantation 1993; 56: 75-82.
3. Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 2007; 46: 13-58.
4. Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89 3048-3054.
5. Maris MB, Niederwieser D, Sandmaier BM, Storer B, Stuart M, Maloney D et al. HLA matched unrelated donor hematopoeitic cell transplantation after nonmyeloablative conditoning for patients with hematologic malignancies. Blood 2003, 102: 2021-2030.
6. Jacobson P, Rogosheske, J, Barker JN, Green K, Ng J, Weidorf D et al Relations of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 2005; 78: 486-500.
7. Jenke A, Renner O, Richte M, Freiberg-Richter J, Platzbecker U, Helwig A et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 2001; 15: 176-184.
8. Giaccone L, McCune JS, Maris MB, Gooley TA, Sandmaier BM, Slattery JT et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 2005; 106: 4381-4388.
9. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamai M et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005; 438: 803-819.
10. Mack GS. Cancer researchers usher in dog days of medicine. Nat Med 2005; 11: 1018.
11. Hilgendorf I, Weirich V, Zeng L, Koppitz E, Wegener R, Freund M et al Canine haematopoietic chimerism analyses by semiquantitative fluorescence detection of variable number of tandem repeat polymorphism. Vet Res Commun 2005; 29: 103-110.
12. Lange S, Brandt B, Riebau F, Vogel H, Weirich V, Hilgendorf I et al Hematopoietic cell lysate vaccinations and bone marrow enrichment with donor-derived dendritic cells for engraftment promotion after non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37 (Suppl 1): S62 (abstract 386).
13. Shaw LM, Holt DW, Oellerich M, Meiser B, van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: Report of a roundtable discussion. Ther Drug Monit 2001; 23: 305-315.
14. Nash RA, Johnston L, Parker P, McCune JS, Storer B, Slattery JT et al A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2005; 11: 495-505.
15. Jacobson P, Green K, Rogosheske J, Brunstein C, Ebeling B, DeFor T et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 2007; 47: 6-12.
16. van Hest RM, Doorduijn JK, de Winter BC, Cornelissen JJ, Vulto AG, Oellerich M et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 2007; 29: 353-360.
17. Jain A, Venkataramanan R, Hamad IS, Zuckerman S, Zhang S, Lever J et al. Pharmacokinetics of mycophenolic acid after mycophenolate mofetil administration in liver transplant patients treated with tacrolimus. J Clin Pharmacol 2001; 41: 268-276.
18. van Hest RM, van Gelder T, Vulto AG, Mathot RA. Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 2005; 44: 1083-1096.
19. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998; 34: 429-455.
20. Arns W, Cibrik DM, Walker RG, Mourad G, Budde K, Mueller EA et al. Therapeutic drug monitoring of mycophenolic acid in solid organ transplant patients treated with mycophenolate mofetil: Review of the literature. Transplantation 2006; 82: 1004-1012.
21. Langman LJ, Shapiro AM, Lakey JR, LeGatt DF, Kneteman NM; Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Transplantation 1996; 61: 87-92.
22. Lupu M, McCune JS, Kuhr CS, Gooley T, Storb R. Pharmacokinetics of oral mycophenolate mofetil in dog: Bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 2006; 12: 1352-1354.
23. Smak Gregoor PJ, van Gelder T, Hesse CJ, van der Mast BJ, van Besouw NM, Weimar W. Mycophenolic acid plasma concentrations in kidney allograft recipients with or without cyclosporin: A cross-sectional study. Nephrol Dial Transplant 1999; 14: 706-708.
24. Cattaneo D, Merlini S, Zenoni S, Baldelli S, Gotti, E, Remuzzi G et al. Influence of co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. Am J Transplant 2005; 5: 2937-2944.
25. Hohage, H, Zeh M, Heck M, Gerhardt UW, Welling U, Suwelack BM. Differential effects of cyclosporine and tacrolimus on mycophenolate pharmacokinetics in patients with impaired kidney function. Transplant Proc 2005; 37: 1748-1750.
26. Pawinski T, Durlik M, Szlaska I, Urbanowicz A, Majchrnak J, Gralak B. Comparison of mycophenolic acid pharmacokinetic parameters in kidney transplant patients within the first 3 months post-transplant. J Clin Pharm Ther 2006; 31: 27-34.
27. Osunkwo I, Bessmertny O, Harrison L, Cheung YK, Van de Ven C, del Toro G et al. A pilot study of tacrolimus and mycophenolate mofetil graft-versus-host disease prophylaxis in childhood and adolescent allogeneic stem cell transplant recipients. Biol Blood Marrow Transplant 2004; 10, 246-258.
28. Maris MB, Sandmaier BM, Storer BE, Maloney DG, Shizuru JA, Agura E et al. Unrelated donor granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell transplantation after nonmyeloablative conditioning: The effect of postgrafting mycophenolate mofetil dosing. Biol Blood Marrow Transplant 2006; 12: 454-465.
29. Hummel,M, Yonan N, Ross H, Miller LW, Sechaud R, Balez S et al. Pharmacokinetics and variability of mycophenolic acid from enteric-coated mycophenolate sodium compared with mycophenolate mofetil in de novo heart transplant recipients. Clin Transplant 2007; 21: 18-23.
30. Filler G. Drug interactions between mycophenolate and cyclosporine. Pediatr Transplant 2004; 8: 201-204.
31. Pape L, Froede K, Strehlau J, Ehrich JH, Offner G. Alterations of cyclosporin A metabolism induced by mycophenolate mofetil. Pediatr Transplant 2003; 7:302-304.
32. John U, Ullrich S, Roskos M, Misselwitz J., Two-hour postdose concentration: A reliable marker for cyclosporine exposure in adolescents with stable renal transplants. Tranplant Proc 2005; 37: 1608-1611.